← Back to patent-cliff list
HTX-201
Tier C — Watch / tradeHTX-201
Kyowa Hakko Kirin Co Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：IDO
Indications (approved)：EB病毒感染, Kidney transplant rejection, Urothelial carcinoma, Solid tumour, 转移性上皮癌
Regional status
US
Discontinued
2016-08-01
EU
Phase II
2026-08-20
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of HTX-201?
Approved indications include: EB病毒感染, Kidney transplant rejection, Urothelial carcinoma, Solid tumour, 转移性上皮癌.
When does the HTX-201 patent expire?
No public expiry year is available for HTX-201 yet; this page updates once verified.
How do I get a quote for HTX-201 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29